635 related articles for article (PubMed ID: 34673335)
1. SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.
Salimi-Jeda A; Abbassi S; Mousavizadeh A; Esghaie M; Bokharaei-Salim F; Jeddi F; Shafaati M; Abdoli A
Int Immunopharmacol; 2021 Dec; 101(Pt A):108232. PubMed ID: 34673335
[TBL] [Abstract][Full Text] [Related]
2. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era.
Volkan E
Mol Biotechnol; 2021 Oct; 63(10):885-897. PubMed ID: 34145550
[TBL] [Abstract][Full Text] [Related]
3. The Current Status and Challenges in the Development of Vaccines and Drugs against Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2).
Beeraka NM; Tulimilli SV; Karnik M; Sadhu SP; Pragada RR; Aliev G; Madhunapantula SV
Biomed Res Int; 2021; 2021():8160860. PubMed ID: 34159203
[TBL] [Abstract][Full Text] [Related]
4. Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.
Zhang Y; Banga Ndzouboukou JL; Gan M; Lin X; Fan X
Front Immunol; 2021; 12():771242. PubMed ID: 34880867
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Gong W; Parkkila S; Wu X; Aspatwar A
Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
[TBL] [Abstract][Full Text] [Related]
6. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
Front Immunol; 2021; 12():658519. PubMed ID: 34276652
[TBL] [Abstract][Full Text] [Related]
7. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.
Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R
Int Immunopharmacol; 2021 Aug; 97():107622. PubMed ID: 33895475
[TBL] [Abstract][Full Text] [Related]
8. COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies.
Raman R; Patel KJ; Ranjan K
Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356617
[TBL] [Abstract][Full Text] [Related]
9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
10. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
Chauhan N; Soni S; Gupta A; Aslam M; Jain U
J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
[TBL] [Abstract][Full Text] [Related]
11. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
Bui NN; Lin YT; Huang SH; Lin CW
Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
[TBL] [Abstract][Full Text] [Related]
12. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
Policard M; Jain S; Rego S; Dakshanamurthy S
Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.
Soni B; Kabra R; Singh S
J Interferon Cytokine Res; 2021 Jul; 41(7):244-257. PubMed ID: 34280026
[TBL] [Abstract][Full Text] [Related]
15. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
[TBL] [Abstract][Full Text] [Related]
16. Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.
Abdullahi IN; Emeribe AU; Adekola HA; Abubakar SD; Dangana A; Shuwa HA; Nwoba ST; Mustapha JO; Haruna MT; Olowookere KA; Animasaun OS; Ugwu CE; Onoja SO; Gadama AS; Mohammed M; Daneji IM; Amadu DO; Ghamba PE; Onukegbe NB; Shehu MS; Isomah C; Babayo A; Ahmad AE
Hum Vaccin Immunother; 2021 Mar; 17(3):620-637. PubMed ID: 32936732
[TBL] [Abstract][Full Text] [Related]
17. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
19. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2.
Mudgal R; Nehul S; Tomar S
Hum Vaccin Immunother; 2020 Dec; 16(12):2921-2931. PubMed ID: 32931361
[TBL] [Abstract][Full Text] [Related]
20. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
